Shares of Kura Oncology Inc. (NASDAQ:KURA) saw an uptick in trading volume on Thursday . 4,560,252 shares traded hands during mid-day trading, an increase of 724% from the previous session’s volume of 553,119 shares.The stock last traded at $5.71 and had previously closed at $4.36.

KURA has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a report on Wednesday, July 13th. Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $16.00 price objective on shares of Kura Oncology in a report on Tuesday, June 21st.

The firm’s market cap is $95.15 million. The firm has a 50 day moving average price of $3.81 and a 200 day moving average price of $3.65.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Wednesday, August 10th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.02. On average, equities analysts expect that Kura Oncology Inc. will post ($1.72) EPS for the current year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.